Targeting hepatocellular carcinoma growth and metabolism:A synergistic approach with para-toluenesulfonamide and radiofrequency ablation  

作　　者：Na Liu Jianzeng Zhang Jiaojiao Wu Fan Feng Yantao Chai Yongwu Li Bo Liu 

机构地区：[1]Department of Nuclear Medicine,The Fifth Medical Center of PLA General Hospital,Beijing 100039,China [2]Clinical Laboratory,The Fifth Medical Center of PLA General Hospital,Beijing 100039,China [3]Department of Hepatology,The Fifth Medical Center of PLA General Hospital,Beijing 100039,China

出　　处：《iLIVER》2024年第3期32-40,共9页国际肝胆健康（英文）

基　　金：supported by the National Natural Science Foundation of China[No.81572461].

摘　　要：Background and aims:Hepatocellular carcinoma(HCC)is one of the most prevalent and lethal forms of cancer,posing challenges to standard treatment methods.Radiofrequency ablation(RFA)has emerged as a valuable technique for the local control of advanced HCC,especially in cases unsuitable for surgical resection.Paratoluenesulfonamide(PTS)has demonstrated antitumor properties in various cancers,yet its efficacy against HCC remains underexplored.The present study aims to investigate the therapeutic potential of PTS in HCC and examine potential synergistic effects with RFA.Methods:PTS was injected directly into subcutaneous tumor tissues and its effects on cell survival,gene expression,and metabolic activity in HCC cells were evaluated.The effect of PTS and RFA in combination on HCC growth was examined using a nude mouse model of subcutaneous HCC.Data were visualized using heat maps.Results:PTS inhibited the survival of HCC cells in a dose-dependent manner,modulating the expression of key genes related to cell survival,apoptosis,epithelial–mesenchymal transition,and proliferation.The combination of PTS and RFA markedly enhanced the inhibition of HCC tumor growth and induced alterations in cellular metabolism.Conclusion:Combining PTS and RFA may be a promising approach to improve the efficacy of HCC treatment.

关 键 词：Hepatocellular carcinoma Para-toluenesulfonamide Radiofrequency ablation therapy PI3K/AKT pathway 

分 类 号：R735.7[医药卫生—肿瘤]